Eli Lilly revenue inches up 2%, Pfizer raises full year outlook

Both Eli Lilly and Pfizer released their latest earnings reports Tuesday morning.

Pfizer recorded a 2% decline in revenues operationally due to “exceptionally strong growth” in Q3 2021. The company also noted that when Paxlovid and Comirnaty were excluded, revenues grew 2% operationally.